Clinical Study
Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure
Table 1
Characteristics of patients with
systemic sclerosis (SSc).
| | All
patients | Diffuse
SSc | Limited
SSc |
| | Women/men () | 102/4 | 71/4 | 31/0 | | Mean age SD, | 54 13 | 52 13
| 56 12
| | years
(range) | (22–80) | (22–80) | (25–77) | | Mean disease duration
SD, | 11 4 | 10 3 | 12 4 | | years (range) | (2–25) | (2–20) | (2–25) |
| | Medications,
% of patients | | | |
| | Calcium—channel blockers | 77% (82) | 76% (57) | 81% (25) | | Angiotensin—converting
enzyme inhibitors | 55% (58) | 63% (47) | 31%
(11) | | Corticosteroids | 29% (31) | 35% (26) | 16% (5) | | Cyclophosphamide | 22% (21) | 23% (17) | 13% (4) | | Mycophenolate
mofetil | 7% (7) | 8% (6) | 3% (1) |
|
|
